Kolorektal Kanser Tedavisinde Kullan\u0131lan EGFR \u0130nhibit\u00f6rlerinin Yol A\u00e7t\u0131\u011f\u0131 Akneiform D\u00f6k\u00fcnt\u00fcye Kar\u015f\u0131 Yenilik\u00e7i Topikal BRAF \u0130nhibit\u00f6r\u00fc LUT014 ile Umut Vadeden Y\u00f6netim<\/p>\n
Kolorektal kanser hastalar\u0131nda s\u0131kl\u0131kla kullan\u0131lan epidermal b\u00fcy\u00fcme fakt\u00f6r\u00fc resept\u00f6r (EGFR) inhibit\u00f6rleri, hastalar\u0131n tedavi s\u00fcrecinde \u00f6nemli yan etkilerden biri olan akneiform d\u00f6k\u00fcnt\u00fcye neden olmaktad\u0131r. Bu r\u00fczg\u00e2rl\u0131 ve a\u011fr\u0131l\u0131 cilt reaksiyonu, \u00f6zellikle ba\u015f, boyun ve \u00fcst g\u00f6vde b\u00f6lgelerinde ortaya \u00e7\u0131karak hastalar\u0131n ya\u015fam kalitesini d\u00fc\u015f\u00fcr\u00fcrken, ciddi vakalarda tedavi dozunun azalt\u0131lmas\u0131 veya kesilmesi zorunlulu\u011funu do\u011furmaktad\u0131r. T\u00fcm bu sorunlar, kanser tedavisinin etkinli\u011fini olumsuz etkileyerek hastalar\u0131n prognostik sonu\u00e7lar\u0131na zarar verebilmektedir. Ancak, The University of Texas MD Anderson Kanser Merkezi\u2019nde ger\u00e7ekle\u015ftirilen yeni bir klinik ara\u015ft\u0131rma, bu soruna etkili bir \u00e7\u00f6z\u00fcm sunan inovatif bir topikal tedavi se\u00e7ene\u011fi olan LUT014\u2019\u00fc g\u00fcndeme getirmektedir.<\/p>\n
EGFR inhibit\u00f6rleri olan cetuximab ve panitumumab gibi ila\u00e7lar, kolorektal kanser tedavisinde t\u00fcm\u00f6r b\u00fcy\u00fcmesini bask\u0131lamak i\u00e7in MAP kinaz (MAPK) sinyal yolunu inhibe eder. Ancak bu etki, epidermal keratinositlerin normal i\u015fleyi\u015finde bozulmaya yol a\u00e7ar ve ciltte inflamatuar bir yan\u0131t ba\u015flat\u0131r. Sonu\u00e7 olarak ortaya \u00e7\u0131kan akneiform d\u00f6k\u00fcnt\u00fc, hastalarda hem fizyolojik hem psikolojik olumsuzluklara neden olarak tedaviye ba\u011fl\u0131 uyumu azaltabilir. EGFR inhibit\u00f6rleri kullanan hastalar\u0131n yakla\u015f\u0131k %75\u2019inde bu cilt reaksiyonunun geli\u015fti\u011fi bildirilmektedir. Bu y\u00fcksek oran, dermatolojik toksisitelerin kontrol\u00fcnde yeni ve etkili yakla\u015f\u0131mlara olan ihtiyac\u0131 g\u00f6zler \u00f6n\u00fcne sermektedir.<\/p>\n
LUT014\u2019\u00fcn yenilik\u00e7i y\u00f6n\u00fc, do\u011frudan MAPK yolundaki \u00f6nemli bir reg\u00fclat\u00f6r olan BRAF kinaz\u0131n\u0131 hedefleyen topikal bir inhibit\u00f6r olmas\u0131d\u0131r. EGFR inhibit\u00f6rlerinin bask\u0131lam\u0131\u015f oldu\u011fu MAPK aktivitesini lokal olarak yeniden aktive ederek keratinositlerin dengesini tekrar sa\u011flar ve inflamasyonu azalt\u0131r. Bu mekanizma, LUT014\u2019\u00fc sadece inflamasyonu veya ikincil enfeksiyonlar\u0131 tedavi eden klasik topikal steroidler ve antibiyotiklerden ay\u0131r\u0131r. B\u00f6ylece sorun, \u015fikayetlerin semptomatik y\u00f6netimi yerine altta yatan molek\u00fcler patolojinin giderilmesine odaklanarak k\u00f6kten \u00e7\u00f6z\u00fcl\u00fcr.<\/p>\n
Alkol bazl\u0131 jel form\u00fclasyonuyla geli\u015ftirilen LUT014, sistemik dola\u015f\u0131ma neredeyse ge\u00e7i\u015f yapmad\u0131\u011f\u0131 i\u00e7in, kemoterap\u00f6tik EGFR inhibit\u00f6rlerinin farmakokinetik profiline zarar vermez ve tedavi etkinli\u011finin d\u00fc\u015fmesinin \u00f6n\u00fcne ge\u00e7er. Bu \u00f6zellik, daha \u00f6nce EGFR inhibit\u00f6rlerine e\u015flik eden dermatolojik yan etki y\u00f6netiminde kar\u015f\u0131la\u015f\u0131lan en b\u00fcy\u00fck zorluklardan biridir. Topikal uygulama ile etkin madde do\u011frudan cildi etkiler ve ek yan etkilere maruz kalma ihtimali minimize edilir. Hem hasta konforu hem de tedavi devaml\u0131l\u0131\u011f\u0131 a\u00e7\u0131s\u0131ndan bu yap\u0131, LUT014 i\u00e7in kritik bir avantaj sa\u011flamaktad\u0131r.<\/p>\n
MD Anderson taraf\u0131ndan y\u00fcr\u00fct\u00fclen, \u00e7ok merkezli, randomize ve plasebo kontroll\u00fc Faz II klinik \u00e7al\u0131\u015fmas\u0131na 23 merkezde toplam 118 orta ve \u015fiddetli akneiform d\u00f6k\u00fcnt\u00fc ya\u015fayan kolorektal kanser hastas\u0131 kat\u0131lm\u0131\u015ft\u0131r. Hastalar 28 g\u00fcnl\u00fck tedavi s\u00fcrecinde %0.1 LUT014, %0.03 LUT014 veya plasebo jelleri alm\u0131\u015ft\u0131r. Tedavi ba\u015far\u0131s\u0131, d\u00f6k\u00fcnt\u00fc \u015fiddetinde en az bir derece azalma veya cilt sa\u011fl\u0131\u011f\u0131 ile ilgili en az 5 kalite ya\u015fam parametresinde iyile\u015fme olarak tan\u0131mlanm\u0131\u015ft\u0131r. Bu kriter, hem klinik hem hastaya \u00f6zel fayday\u0131 \u00f6l\u00e7me a\u00e7\u0131s\u0131ndan yenilik\u00e7i ve kapsaml\u0131 bir de\u011ferlendirme sunmaktad\u0131r.<\/p>\n
\u00c7al\u0131\u015fma sonu\u00e7lar\u0131, %0.1 konsantrasyonlu LUT014 kullanan hastalar\u0131n %69\u2019unda ba\u015far\u0131 elde edildi\u011fini, %0.03 grubunda ba\u015far\u0131 oran\u0131n\u0131n %47.5 oldu\u011funu ortaya koymu\u015ftur. Plasebo grubundaki ba\u015far\u0131 oran\u0131 ise %33 seviyelerinde kalm\u0131\u015ft\u0131r. Bu bulgular LUT014\u2019\u00fcn doz-cevap ili\u015fkisini desteklemi\u015f ve topikal BRAF inhibit\u00f6r\u00fcn\u00fcn etkinli\u011fini net bir \u015fekilde ortaya koymu\u015ftur. Ayr\u0131ca, hastalar\u0131n rapor etti\u011fi ya\u015fam kalitesi verileri, yaln\u0131zca cilt semptomlar\u0131nda de\u011fil, g\u00fcnl\u00fck fonksiyonlar\u0131nda ve psikososyal durumlar\u0131nda da anlaml\u0131 iyile\u015fmeler sa\u011flam\u0131\u015ft\u0131r.<\/p>\n
Tedavi s\u00fcresince bildirilen advers etkiler \u00e7o\u011funlukla 3. dereceyi a\u015fmayan, lokal alkol bazl\u0131 jellere ba\u011fl\u0131 minimal irritasyon bi\u00e7imindeydi. Sistemik yan etkiler g\u00f6zlenmemi\u015f olup, LUT014 g\u00fcvenli ve iyi tolere edilebilir bir tedavi olarak tan\u0131mlanm\u0131\u015ft\u0131r. Kronik antibiyotik veya steroid kullan\u0131m\u0131ndan kaynaklanan diren\u00e7 sorunlar\u0131 ve di\u011fer komplikasyonlar s\u00f6z konusu olmam\u0131\u015ft\u0131r. G\u00fcvenlik ve etkililik dengesi, LUT014\u2019\u00fc kanser hastalar\u0131nda uzun s\u00fcreli kullan\u0131m i\u00e7in ideal bir se\u00e7enek haline getirmektedir.<\/p>\n
\u00c7al\u0131\u015fman\u0131n sonu\u00e7lar\u0131, Nisan 2025\u2019te Amerikan Kanser Ara\u015ft\u0131rmalar\u0131 Derne\u011fi (AACR) Y\u0131ll\u0131k Toplant\u0131s\u0131\u2019nda Dr. Anisha Patel taraf\u0131ndan resmi olarak sunulmu\u015ftur. Dr. Patel, EGFR inhibit\u00f6r\u00fc tedavisi s\u00fcrecinde yan etkilerin azalt\u0131lmas\u0131n\u0131n kanser kontrol\u00fc a\u00e7\u0131s\u0131ndan \u00f6nemini vurgulayarak, LUT014\u2019\u00fcn molek\u00fcler d\u00fczeydeki deste\u011finin yeni bir destekleyici bak\u0131m paradigmas\u0131 olu\u015fturma potansiyeline i\u015faret etti\u011fini belirtmi\u015ftir. Ayr\u0131ca, bu stratejinin di\u011fer kinaz inhibit\u00f6r\u00fc temelli kanser tedavilerinde ortaya \u00e7\u0131kan dermatolojik yan etkiler i\u00e7in de uygulanabilirli\u011finin ara\u015ft\u0131r\u0131ld\u0131\u011f\u0131n\u0131 ifade etmi\u015ftir.<\/p>\n
Faz II sonu\u00e7lar\u0131n\u0131n ard\u0131ndan, LUT014\u2019\u00fcn farkl\u0131 kanser t\u00fcrlerinde ve \u00e7e\u015fitli kinaz inhibit\u00f6r\u00fc tedavilerinde yol a\u00e7t\u0131\u011f\u0131 cilt toksisiteleri i\u00e7in faz III b\u00fcy\u00fck \u00e7apl\u0131 klinik \u00e7al\u0131\u015fmalar\u0131 planlanmaktad\u0131r. Bu geni\u015fletilmi\u015f uygulama alan\u0131, molek\u00fcler d\u00fczeydeki hedeflenmi\u015f yan etki y\u00f6netiminin onkoloji alan\u0131nda k\u00f6kl\u00fc bir d\u00f6n\u00fc\u015f\u00fcme \u00f6nc\u00fcl\u00fck edece\u011finin g\u00f6stergesidir. B\u00f6ylece tedavi ba\u015far\u0131s\u0131zl\u0131klar\u0131n\u0131n \u00f6nlenmesi, ya\u015fam kalitesinin y\u00fckseltilmesi ve ki\u015fiye \u00f6zel tedavi yakla\u015f\u0131mlar\u0131n\u0131n g\u00fc\u00e7lendirilmesi ama\u00e7lanmaktad\u0131r.<\/p>\n
LUT014\u2019\u00fcn geli\u015ftirilme s\u00fcreci Lutris Pharma taraf\u0131ndan desteklenmi\u015f olup, MD Anderson ara\u015ft\u0131rmac\u0131lar\u0131 ile ila\u00e7 firmas\u0131 aras\u0131ndaki i\u015f birli\u011fi s\u00fcrecin bilimsel ve inovatif temelde ilerlemesini sa\u011flam\u0131\u015ft\u0131r. Mevcut ara\u015ft\u0131rma raporlar\u0131 ve \u015feffafl\u0131k prensipleri gere\u011fi, \u00e7al\u0131\u015fma yazarlar\u0131 ve ili\u015fkili kurulu\u015flar detayl\u0131 bir \u015fekilde a\u00e7\u0131klanm\u0131\u015f, akademi-sanayi ortakl\u0131\u011f\u0131n\u0131n \u00f6nemi bir kez daha peki\u015ftirilmi\u015ftir.<\/p>\n
Sonu\u00e7 olarak, EGFR inhibit\u00f6rlerinin yol a\u00e7t\u0131\u011f\u0131 akneiform d\u00f6k\u00fcnt\u00fclerin y\u00f6netiminde LUT014 gibi molek\u00fcler hedefe y\u00f6nelik yakla\u015f\u0131mlar, tedavi devam\u0131n\u0131 g\u00fcvence alt\u0131na alarak kolorektal kanser hastalar\u0131n\u0131n ya\u015fam kalitesinde anlaml\u0131 ilerlemeler sa\u011flamaktad\u0131r. Bu geli\u015fme, onkolojik tedavi s\u00fcre\u00e7lerinde yan etkilerin sadece bast\u0131r\u0131lmas\u0131ndan ziyade patogenezine y\u00f6nelik m\u00fcdahaleyle y\u00f6netilmesinin m\u00fcmk\u00fcn oldu\u011funu g\u00f6stermektedir. Yeni nesil destekleyici onkoloji bak\u0131m modellerinde LUT014, hem hastalar hem de hekimler i\u00e7in umut verici bir se\u00e7ene\u011fi simgelemektedir.<\/p>\n
—<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Haberin Yay\u0131n Tarihi<\/strong>: Web References<\/strong>: Resim Credits<\/strong>: Anahtar Kelimeler<\/strong>: Kolorektal Kanser Tedavisinde Kullan\u0131lan EGFR \u0130nhibit\u00f6rlerinin Yol A\u00e7t\u0131\u011f\u0131 Akneiform D\u00f6k\u00fcnt\u00fcye Kar\u015f\u0131 Yenilik\u00e7i Topikal BRAF \u0130nhibit\u00f6r\u00fc LUT014 ile Umut Vadeden Y\u00f6netim Kolorektal kanser hastalar\u0131nda s\u0131kl\u0131kla kullan\u0131lan epidermal b\u00fcy\u00fcme fakt\u00f6r\u00fc resept\u00f6r (EGFR) inhibit\u00f6rleri, hastalar\u0131n tedavi s\u00fcrecinde \u00f6nemli yan etkilerden biri olan akneiform d\u00f6k\u00fcnt\u00fcye neden olmaktad\u0131r. Bu r\u00fczg\u00e2rl\u0131 ve a\u011fr\u0131l\u0131 cilt reaksiyonu, \u00f6zellikle ba\u015f, boyun ve \u00fcst g\u00f6vde…<\/p>\n","protected":false},"author":1,"featured_media":4100,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[3765,3768,3767,3764,3766],"tmauthors":[],"class_list":{"0":"post-4099","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-egfr-inhibitorlerine-bagli-akneiform-dokuntu-yonetimi","9":"tag-egfr-inhibitorlerine-bagli-cilt-reaksiyonlarinin-molekuler-tedavisi","10":"tag-kolorektal-kanser-tedavisinde-dermatolojik-toksisiteler","11":"tag-kolorektal-kanser-tedavisinde-egfr-inhibitorlerinin-yan-etkileri","12":"tag-lut014-topikal-braf-inhibitoru-kullanimi"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Hedefe-Yonelik-Kolorektal-Kanser-Tedavisine-Bagli-Agrili-Dokuntuye-Jel-Cozumu-1745856862.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/4099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=4099"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/4099\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/4100"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=4099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=4099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=4099"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=4099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nTargeted management of EGFR inhibitor-induced dermatologic toxicity in colorectal cancer patients using a novel topical BRAF inhibitor.<\/p>\n
\nNovel Topical BRAF Inhibitor LUT014 Mitigates EGFR Inhibitor-Induced Acneiform Rash, Enabling Continued Colorectal Cancer Treatment<\/p>\n
\nApril 27, 2025<\/p>\n
\nClinical trial abstract CT018
\nMD Anderson Targeted Therapy
\nColorectal Cancer Overview
\nAACR Annual Meeting 2025
\nMD Anderson AACR Meeting Content<\/p>\n
\nThe University of Texas MD Anderson Cancer Center<\/p>\n
\nCancer treatments, Skin disorders, Drug targets, Colorectal cancer, EGFR inhibitors, Side effects, Cell therapies, Inhibitory effects, Kinase inhibitors, Clinical trials, Drug studies, Drug development, Cancer research<\/p>\n","protected":false},"excerpt":{"rendered":"